An Alternative Route — within a Major Company: Selling Out, but for Greater Resources and Security
‘One of my reasons for leaving Texas Instruments, Abbott Laboratories and Allied Corporation to head up Biogen was to get away from the mega-corporation lifestyle. I’m conscious that there’s some tendency for some biotechnology companies to be taken over by big corporates. We’ve seen how Genentech have sold out a portion of their shares to Hoffman-La Roche. If I think about Biogen’s prospects for continued independence, I’d say that I think biotechnology companies — not unlike the last 30 years of other high technology industries that have developed — as high technology emerging growth companies, can stay independent if they want to.
KeywordsVenture Capital Alternative Route Biotechnology Company Biotech Company Major Company
Unable to display preview. Download preview PDF.